{"id":"insulin-glulisine-tid","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201613","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glulisine is a recombinant human insulin analog with rapid onset and short duration of action. It binds to the insulin receptor with similar affinity to human insulin but has faster absorption and earlier peak action, making it suitable for mealtime glucose control. It promotes glucose uptake into peripheral tissues and suppresses hepatic glucose production.","oneSentence":"Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:11.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT01855243","phase":"NA","title":"Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM","status":"COMPLETED","sponsor":"Cairo University","startDate":"2010-03","conditions":"Diabetes Mellitus (DM)","enrollment":63},{"nctId":"NCT01768559","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-01","conditions":"Type 2 Diabetes","enrollment":894},{"nctId":"NCT01204593","phase":"PHASE4","title":"baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 1","enrollment":206},{"nctId":"NCT00596687","phase":"PHASE4","title":"Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-12","conditions":"Type 2 Diabetes, Inpatient Hyperglycemia","enrollment":234},{"nctId":"NCT00394407","phase":"PHASE4","title":"Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-09","conditions":"Diabetes, Hyperglycemia","enrollment":130},{"nctId":"NCT00135083","phase":"PHASE3","title":"Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Diabetes Mellitus, Type 2","enrollment":347},{"nctId":"NCT00174668","phase":"PHASE3","title":"Insulin Glulisine in Diabetes Mellitus, Type 2","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 2","enrollment":311}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HMR1964","Device: Disposable self-injector prefilled pen (Apidra® Solostar®)"],"phase":"phase_3","status":"active","brandName":"Insulin glulisine TID","genericName":"Insulin glulisine TID","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}